Chemical and pharmacological chaperones: Application for recombinant protein production and protein folding diseases

Current Medicinal Chemistry

Volumn 18, Issue 1, 2011, Pages 1-15

  Rajan, Rahul S ^a   Tsumoto, Kouhei ^b   Tokunaga, Masao ^c   Tokunaga, Hiroko ^c   Kita, Yoshiko ^d   Arakawa, Tsutomu ^e  

^a Process and Product Development   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e ALLIANCE PROTEIN LABORATORIES   (United States)

Author keywords

Chemical chaperone; Halophile; Osmolyte; Pharmacological chaperon; Recombinant protein

Indexed keywords

AMYLASE; ARGININE; ARGIPRESSIN RECEPTOR; BETA ALANINE; CHAPERONE; GLYCEROL; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PERIPLASMIC PROTEIN; PROLINE; RECOMBINANT PROTEIN; SARCOSINE; SUCROSE; TAURINE; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TREHALOSE; TRIMETHYLAMINE OXIDE;

ARTICLE; BIOTECHNOLOGY; CELL INCLUSION; CHROMOHALOBACTER; CYTOPLASM; DIALYSIS; ENDOPLASMIC RETICULUM; ESCHERICHIA COLI; HALOPHILE; HETEROLOGOUS EXPRESSION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; NEPHROGENIC DIABETES INSIPIDUS; OSMOTIC PRESSURE; PRODUCT DEVELOPMENT; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SARS CORONAVIRUS;

ARGININE; MOLECULAR CHAPERONES; OSMOLAR CONCENTRATION; PROTEIN FOLDING; RECOMBINANT PROTEINS;

EID: 78751550063     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711793979698     Document Type: Article

References (137)

1. Porro, D.; Sauer, M.; Branduardi, P.; Mattanovich, D. Recombinant protein production in yeasts. Mol. Biotechnol., 2005, 31, 245-259.
2. Warnock, J. N.; Al-Rubeai, M. Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol. Appl. Biochem., 2006, 45, 1-12.
3. Sivakumar, G. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots. Biotechnol. J., 2006, 1, 1419-1427.
4. Arakawa, T.; Tsumoto, K.; Kita, Y.; Chang, B.; Ejima, D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids, 2007, 33, 587-605.
5. Maggon, K. Monoclonal antibody "gold rush". Curr. Med. Chem., 2007, 14, 1978-1987.
6. Alberch, J.; Perez-Navarro, E.; Canals, J. M. Neutrotrophic factors in Huntington's disease. Prog. Brain Res., 2004, 146, 195-229.
7. Johnston, T. H.; Brotchie, J. M. Drugs in development for Parkinson's disease. Curr. Opin. Investig. Drugs, 2004, 5, 720-726.
8. Sellal, F.; Nieoullon, A.; Michel, G.; Michel, B. F.; Lacomblez, L.; Greets, H.; Delini-Stula, A.; Bentue-Ferrer, D.; Bordet, R.; Allain, H. Pharmacology of Alzheimer's disease: where do we go from here? Therapie, 2005, 60, 89-107.
9. Kelly, J. W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Str. Biol., 1998, 8, 101-106.
10. Lomas, D. A.; Carrell, R. W. Serpinopathies and the conformational dementias. Nat. Rev. Genet., 2002, 3, 759-768.
11. Stefani, M.; Dobson, C. M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Biol., 2003, 81, 678-699.
12. Stefani, M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta, 2004, 1739, 5-25.
13. Thomas, P. J.; Qu, B. H.; Pedersen, P. L. Defective protein folding as a basis of human disease. Trends Biosci., 1995, 20, 456-459.
14. Welch, W. J.; Brown, C. R. Influence of molecular and chemical chaperones on protein folding. Cell stress chaperones, 1996, 1, 109-115.
15. Yancey, P. H.; Clark, M. E.; Hand, S. C.; Bowlus, R. D.; Somero, G. Living with water stress: evolution of osmolyte systems. Science, 1982, 217, 1214-1222.
16. Yancey, P. H. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J. Exp. Biol., 2005, 208, 2819-2830.
17. Arakawa, T.; Timasheff, S. N. Preferential interactions of proteins with solvent components in aqueous amino acid solutions. Arch. Biochem. Biophys., 1983, 224, 169-177.
18. Arakawa, T.; Timasheff, S. N. The mechanism of action of Na glutamate, lysine HCl, and piperazine-N, N'-bis (2-tehanesulfonic acid) in the stabilization of tubulin and microtubule formation. J. Biol. Chem., 1984, 259, 4979-4986.
19. Arakawa, T.; Timasheff, S. N. The stabilization of proteins by osmolytes. Biophys. J., 1985, 47, 411-414.
20. Qu, Y.; Bolen, C. L.; Bolen, D. W. Osmolyte-driven contraction of a random coil protein. Proc. Natl. Acad. Sci. USA., 1998, 95, 9628-9273.
21. Uversky, V. N.; Li, J.; Fink, A. L. Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Lett., 2001, 509, 31-35.
22. Ishibashi, M.; Sakashita, K.; Tokunaga, H.; Arakawa, T.; Tokunaga, M. Activation of halophilic nucleoside diphosphate kinase by a non-ionic osmolyte, trimethylamine N-oxide. J. Protein Chem., 2003, 22, 345-351.
23. Kim, S. H.; Yan, Y. B.; Zhou, H. M. Role of osmolytes as chemical chaperones during the refolding of aminoacylase. Biochem. Cell Biol., 2006, 84, 30-38.
24. Street, T. O.; Bolen, D. W.; Rose, G. D. A molecular mechanism for osmolyte-induced protein stability. Proc. Natl. Acad. Sci. USA., 2006, 103, 13997-14002.
25. Mukaiyama, A.; Koga, Y.; Takane, K.; Kanaya, S. Osmolyte effect on the stability and folding of a hyperthermophilic protein. Proteins, 2008, 71, 110-118.
26. Lee, S.-H.; Carpenter, J. F.; Chang, B. S.; Randolph, T. W.; Kim, Y.-S. Effects of solutes on solubilization and refolding of proteins from inclusion bodies with high hydrostatic pressure. Protein Sci., 2006, 15, 304-313.
27. Fujii, T.; Ohkuri, T.; Onodera, R.; Ueda, T. Stable supply of large amounts of human Fab from the inclusion bodies in E. coli. J. Biochem., 2007, 141, 699-707.
28. Bai, C. X.; Biwersi, J.; Verkman, A. S.; Matthay, M. A. A mouse model to test the in vivo efficacy of chemical chaperones. J. Pharmacol. Toxicol. Methods, 1998, 40, 39-45.
29. Fischer, H.; Fukuda, N.; Barbry, P.; Illek, B.; Sartori, C.; Matthay, M. A. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 281, L52-57.
30. Morello, J. P.; Petaja-Repo, U. E.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci., 2000, 21, 466-469.
31. Cohen, F. E.; Kelly, J. W. Therapeutic approaches to proteinmisfolding diseases. Nature, 2003, 426, 905-909.
32. Conn, P. M.; Leanos-Miranda, A.; Janovick, J. A. Protein origami: therapeutic rescue of misfolded gene products. Mol. Interv., 2002, 2, 308-316.
33. Arakawa, T.; Tsumoto, K. The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. Biochem. Biophys. Res. Commun., 2003, 304, 148-152.
34. Ishibashi, M.; Tsumoto, K.; Ejima, D.; Arakawa, T.; Tokunaga, M. Characterization of arginine as a solvent additive: a halophilic enzyme as a model protein. Protein Pept. Lett., 2005, 12, 649-653.
35. Arakawa, T.; Kita, Y.; Tsumoto, K.; Ejima, D.; Fukada, H. Aggregation suppression of proteins by arginine during thermal unfolding. Protein Pept. Lett., 2006, 13, 921-927.
36. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S. N. Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects. Biophys. Chem., 2007, 127, 1-8.
37. Orsini, G.; Goldberg, M. E. The renaturation of reduced chymotrypsinogen A in guanidine HCl. Refolding versus aggregation. J. Biol. Chem., 1978, 253, 3453-3458.
38. Anfinsen, C. B. Principles that govern the folding of protein chains. Science, 1973, 181, 223-230.
39. Anfinsen, C. B.; Scheraga, H. A. Experimental and theoretical aspects of protein folding. Adv. Protein Chem., 1975, 29, 205-300.
40. Anfinsen, C. B. The formation and stabilization of protein structure. Biochem. J., 1972, 128, 737-749.
41. Lumry, R.; Eyring, H. Conformation changes of proteins. J. Phys. Chem., 1954, 58, 110-120.
42. Sanchez-Ruiz, J. M. Theoretical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophys. J., 1992, 61, 921-935.
43. Buchner, J.; Rudolph, R. Renaturation, purificationa nd characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology, 1991 9, 157-162.
44. Lin, W. J.; Traugh, J. A. Renaturation of casein kinase II from recombinant subunits produced in Escherichia coli: purification and characterization of the reconstituted holoenzyme. Protein Expr. Purif., 1993, 4, 256-264.
45. Hsih, M. H.; Kuo, J. C.; Tsai, H. J. Optimization of the solubilization and renaturation of fish growth hormone produced by Escherichia coli. Appl. Microbiol. Biotechnol., 1997, 48, 66-72.
46. Lilie, H.; Schwarz, E.; Rudolph, R. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotech., 1998, 9, 497-501.
47. Arakawa, T.; Katsuyama, I.; Kumagai, I.; Tsumoto, K. A magic agent in protein refolding: arginine. Tanpakushitsu Kakusan Koso, 2003, 48, 2310-2317.
48. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Philo, J. S.; Arakawa, T. Role of arginine in protein refolding, solubilization, and purification. Biotechnol. Prog., 2004, 20, 1301-1308.
49. Armstrong, N.; De Lencastre, A.; Gouzux, E. A new protein folding screen: application to the ligand binding domains of a glutamate and kainate receptor and to lysozyme and carbonic anhydrase. Protein Sci., 1999, 8, 1475-1483.
50. Seefeldt, M. B.; Rosendahl, M. S.; Cleland, J. L.; Hesterberg, L. K. Application of high hydrostatic pressure to dissociate aggregates and refold proteins. Curr. Pharm. Biotechnol., 2007, 10, 447-455.
51. Qoronfleh, M. W.; Hesterberg, L. K.; Seefeldt, M. B. Confronting high-throughput protein refolding using high pressure and solution screens. Protein Expr. Purif., 2007, 55, 209-224.
52. http://refold.med.monash.edu.au/
53. Chow, M. K.; Amin, A. A.; Fulton, K. F.; Whisstock, J. C.; Buckle, A. W.; Bottomley, S. P. REFOLD: an analytical database of protein refolding methods. Protein Expr. Purif., 2005, 46, 166-171.
54. Chow, M. K.; Amin, A. A.; Fulton, K. F.; Feronando, T.; Kamau, L.; Batty, C.; Louca, M.; Ho, S.; Whisstock, J. C.; Bottomley, S. P.; Buchkle, A. W. The REFOLD database: a tool for the optimization of protein expression and refolding. Nucleic Acid Res., 2006, 34, D207-212.
55. Tsumoto, K.; Ejima, D.; Kumagai, I.; Arakawa, T. Practical consideration in refolding proteins from inclusion bodies. Protein Expr. Purif., 2003, 28, 1-8.
56. Baskakov, I.; Bolen, D. W. Forcing thermodynamically unfolded proteins to fold. J. Biol. Chem., 1998, 273, 4831-1834.
57. Chow, M. K.; Devlin, G. L.; Bottomley, S. P. Osmolytes as modulators of conformational changes in serpins. Biol. Chem., 2001, 382, 1593-1599.
58. Ou, W. B.; Park, Y. D.; Zhou, H. M. Effect of osmolytes as folding acids on creatine kinase refolding pathway. Int. J. Biochem. Cell Biol., 2002, 34, 136-147.
59. Pradeep, L.; Udgaonkar, J. B. Osmolytes induce structure in an early intermediate on the folding pathway of barstar. J. Biol. Chem., 2004, 279, 40303-40313.
60. Rösgen, J.; Pettitt, B. M.; Bolen, D. W. Protein folding, stability, and solvation structure in osmolyte solutions. Biophys. J., 2005, 89, 2988-2997.
61. Kumar, R. Osmolyte-induced folding of an intrinsically disordered activation function subdomain of glucocorticoid receptor. J. Recept. Signal Transduct. Res., 2008, 28, 465-474.
62. Hu, C. Y.; Pettitt, B. M.; Rösgen, J. Osmolyte solutions and protein folding. F1000 Biol. Rep., 2009, 1, 1-3.
63. Lu, D.; Jimenez, X.; Zhang, H.; Bohlen, P.; Witte, L.; Zhu, Z. FabscFv fusion protein: an efficient approach to production of bispecific antibody fracgments. J. Immunol. Methods, 2002, 267, 213-226.
64. Stockwin, L. H.; Holmes, S. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther., 2003, 3, 1133-1152.
65. Wuertzer, C. A.; Sullivan, M. A.; Qiu, X.; Federoff, H. J. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther., 2008, 16, 481-486.
66. Sawano, H.; Koumoto, Y.; Ohta, K.; Sasaki, Y.; Segawa, S.; Tachibana, H. Efficient in vitro folding of the three-disulfide derivatives of hen lysozyme in the presence of glycerol. FEBS Lett., 1992, 303, 11-14.
67. Samuel, D.; Kumar, T. K. S.; Ganesh, G.; Jayaraman, G.; Yang, P.-W.; Chang, M.-M.; Trivedi, V. D.; Wang, S.-L.; Hwang, K.-C.; Chang, D.-K.; Yu, C. Proline inhibits aggregation during protein refolding. Protein Sci., 2000, 9, 344-352.
68. Zhao, J.-C.; Zhao, Z.-D.; Wang, W.; Gao, X.-M. Prokaryotic expression, refolding, and purification of fragment 450-650 of the spike protein of SARS-coronavirus. Protein Expr. Purif., 2005, 39, 169-174.
69. Talmadge, K.; Gilbert, W. Cellular location affects protein stability in Escherichia coli. Proc. Natl. Acad. Sci. USA., 1982, 79, 1830-1833.
70. Barth, S.; Huhn, M.; Matthey, B.; Klimka, A.; Galinski, E. A.; Engert, A. Compatible-solute-supported periplasmic expression of functiona recombinant proteins under stress conditions. Appl. Environ. Microbiol., 2000, 66, 1572-1579.
71. Schäffner, J.; Winter, J.; Rudolph, R.; Schwarz, E. Cosecretion of chaperones and low-molecular-size medium additives increases the yield of recombinant disulfide-bridged proteins. Appl. Environ. Microbiol., 2001, 67, 3994-4000.
72. Buchner, J.; Schmidt, M.; Fuchs, M.; Jaenicke, R.; Rudolph, R.; Schmid, F.; Kiefhaber, T. GroE facilitates refolding of citrate synthase by suppressing aggregation. Biochemistry, 1991, 30, 1586-1591.
73. Hendrick, J. P.; Hartl, F. U. Molecular chaperone functions of heatshock proteins. Annu. Rev. Biochem., 1993, 62, 349-384.
74. Esposito, D.; Chatterjee, D. K. Enhancement of soluble protein expression through the use of fusion tags. Curr. Opin. Biotechnol., 2006, 17, 353-358. (Pubitemid 44163452)
75. Backwell, J. R.; Horgan, R. A novel strategy for production of a highly expressed recombinant protein in an active form. FEBS Lett., 1991 295, 10-12.
76. Van Wuytswinkel, O.; Savino, G.; Briat, J. Purification and characterization of recombinant pea-seed ferritins expressed in Escherichia coli: influence of N-terminus deletions on protein solubility and core formation in vitro. Biochem. J., 1995, 305, 253-261.
77. Kennedy, S. P.; Ng, W. V.; Salzberg, S. L.; Hood, L.; DasSarma, S. Understanding the adaptation of Halobacterium species NRC-1 to its extreme environment through computational analysis of its genome sequence. Genome Res., 2001, 11, 1641-1650.
78. Baliga, N. S.; Bonneau, R.; Facciotti, M. T.; Pan, M.; Glusman, G.; Deutsch, E. W.; Shannon, P.; Chiu, Y.; Weng, R. S.; Gan, R. R.; Hung, P.; Date, S. V.; Marcotte, E.; Hood, L.; Ng, W. V. Genome sequence of Haloarcula marismortui: a halophilic archaeon from the Dead Sea. Genome Res., 2004, 14, 2221-2234.
79. Oren, A.; Larimer, F.; Richardson, P.; Lapidus, A., Csonka, L. N. How to be moderately halophilic with broad salt tolerance: clues from the genome of Chromohalobacter salexigens. Extremophiles, 2005, 9, 275-279.
80. Ventosa, A.; Nieto, J. J.; Oren, A. Biology of moderately halophilic aerobic bacteria. Microbiol. Mol. Biol. Rev., 1998, 62, 504-544.
81. Galinski, E. A. Osmoadaptation in bacteria. Adv. Microb. Physiol., 1995, 37, 272-328.
82. Vargas, C.; Nieto, J. J. Genetic tools for the manipulation of moderately halophilic bacteria of the family Halomonadaceae. Methods Mol. Biol., 2004, 267, 183-208.
83. Afendra, A. S.; Vargas, C.; Nieto, J. J.; Drainas, C. Gene transfer and expression of recombinant proteins in moderately halophilic bacteria. Methods Mol. Biol., 2004, 267, 209-223.
84. Arvanitis, N.; Vargas, C.; Tegos, G.; Perysinakis, A.; Nieto, J. J.; Ventosa, A.; Drainas, C. Development of a gene reporter system in moderately halophilic bacteria by employing the ice nucleation gene of Pseudomonas syringae. Appl. Environ. Microbiol., 1995, 61, 3821-3825.
85. Douka, E.; Christogianni, A.; Koukkou, A. I.; Afendra, A. S.; Drainas, C. Use of a green fluorescent protein gene as a reporter in Zymomonas mobilis and Halomonas elongate. FEMS Microbiol. Lett., 2001, 201, 221-227.
86. Frillingos, S.; Linden, A.; Niehaus, F.; Vargas, C.; Nieto, J. J.; Ventosa, A.; Antranikian, G.; Drainas, C. Cloning and expression of alpha-amylase from the hyperthermophilic archaeon Pyrococcus woesei in the moderately halophilic bacterium Halomonas elongata. J. Appl. Microbiol., 2000, 88, 495-503.
87. Nagayoshi, C.; Tokunaga, H.; Hayashi, A.; Harazono, H.; Hamasaki, K.; Ando, A.; Tokunaga, M. Efficient expression of haloarchaeal nucleoside diphosphate kinase via strong porin promoter in moderately halophilic bacteria. Protein Pept. Lett., 2006, 13, 611-615.
88. Nagayoshi, C.; Ishibashi, M.; Tokunaga, M. Purification and characterization of human brain serine racemase expressed in moderately halophilic bacteria. Protein Pept. Lett., 2009, 16, 201-206.
89. Nagayoshi, C.; Ishibashi, M.; Kita, Y.; Matsuoka, M.; Nishimoto, I.; Tokunaga, M. Expression, refolding and characterization of human brain serine racemase in Escherichia coli with N-terminal Histag. Protein Pept. Lett., 2005, 12, 487-490.
90. Gelman, M. S.; Kopito, R. R. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J. Clin. Invest., 2002, 110, 1591-1597.
91. Kartner, N.; Augustinas, O.; Jensen, T. J.; Naisith, A. L.; Riordan, J. R. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat. Genet., 1992, 1, 321-327.
92. Kopito, R. R. Biosynthesis and degradation of CFTR. Physiol. Rev., 1999, 79 (Suppl.), S167-173.
93. Ward, C. L.; Omura, S.; Kopito, R. R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell., 1995, 83, 121-127.
94. Sharma, M.; Benharouga, M.; Hu, W.; Lukas, G. L. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem., 2001, 276, 8942-8950.
95. Dalemans, W.; Barbry, P.; Champigny, G.; Jallat, S.; Dott, K.; Dreyer, D.; Crystal, R. G.; Pavirani, A.; Lecocq, J. P.; Lazdunski, M. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature, 1991, 354, 526-528.
96. Dalemans, W.; Hinnrasky, J.; Slos, P.; Dreyer, D.; Fuchey, C.; Pavirani, A.; Puchelle, E. Immunocytochemical analysis reveals differences between the subcellular localization of normal and delta Phe508 recombinant cystic fibrosis transmembrane conductance regulator. Exp. Cell Res., 1992, 201, 235-240.
97. Sato, S.; Ward, C. L.; Krouse, M. E.; Wine, J. J.; Kopito, R. R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem., 1996, 271, 635-638. (Pubitemid 26034907)
98. Burrows, J. A.; Willis, L. K.; Perlmutter, D. H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. USA., 2000, 97, 1796-1801.
99. Langley, J. M.; Balfe, J. W.; Selander, T.; Ray, P. N.; Clarke, J. Y. Autosomal recessive inheritance of vasopressin-resistant diabetes insipidus. Am. J. Med. Genet, 1991, 38, 90-94.
100. Tamarappoo, B. K.; Yang, B.; Verkman, A. S. Misfolding of mutant aquaporin-2 water channels in nephrogenic diabetes insipidus. J. Biol. Chem., 1999, 274, 34825-34831.
101. Tamarappoo, B. K.; Verkman, A. S. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus an dcorrection by chemical chaperones. J. Cin. Invest., 1998, 101, 2257-2267.
102. Deen, P. M. T.; Marr, N.; Kamsteeg, E. J.; Van Balkom, B. W. M. Nephrogenic diabetes insipidus. Curr. Opin. Nephrol. Hypertens., 2000, 9, 591-595.
103. Robben, J. H.; Knoers, N. V. A. M.; Deen, P. M. T. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am. J. Physiol., 2005, 289, F265-272.
104. Robben, J. H.; Sze, M.; Knoers, N. V. A. M.; Deen, P. M. T. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol. Biol. Cell, 2006, 17, 379-386.
105. Lin, T. Y.; Timasheff, S. N. On the role of surface tension in the stabilization fo globular proteins. Protein Sci., 1996, 5, 372-381.
106. Beck, D. A.; Bennion, B. J.; Alonso, D. O.; Daggett, V. Simulations of macromolecules in protective and denaturing osmolytes: properties of mixed solvent systems and their effects on water and protein structure and dynamics. Methods Enzymol., 2007, 428, 373-396.
107. Arakawa, T.; Kita. Y.; Timasheff, S. N. Protein precipitation and denaturation by dimethyl sulfoxide. Biophys. Chem., 2007, 131, 62-70.
108. Arakawa, T.; Carpenter, J. F.; Kita, Y.; Crowe, J. H. The basis for toxicity of certain cryoprotectants. Cryobiology, 1990, 27, 401-415.
109. Morello, J. P.; Salahpour, A.; Laperrière, A.; Bernier, V.; Arthus, M. F.; Lonergan, M.; Petäjä-Repo, U.; Angers, S.; Morin, D.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones rescue cellsurface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest., 2000, 105, 887-895.
110. Bernier. V.; Morello, J. P.; Zarruk. A.; Debrand, N.; Salahpour, A.; Lonergan, M.; Arthus, M. F.; Laperrière, A.; Brouard, R.; Bouvier, M.; Bichet, D. G. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol., 2006, 17, 232-243.
111. Kobayashi, H.; Ogawa, K.; Yao, R.; Lichtarge, O.; Bouvier, M. Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic, 2009, 10, 1019-1033.
112. Guay-Broder, C.; Jacobson, K. A.; Barnoy, S.; Cabantchik, Z. I.; Guggino, W. B.; Zeitlin, P. L.; Turner, R. J.; Vergara, L.; Eidelman, O.; Pollard, H. B. A1 receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry, 1995, 34, 9079-9087.
113. Srivastava, M.; Eidelman, O.; Pollard, H. B. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol. Med., 1999, 5, 753-767.
114. Eidelman, O.; Zhang, J.; Srivastava, M.; Pollard, H. B. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery. Am. J. Pharmacogenom., 2001, 1, 221-238.
115. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem., 1982, 42, 65-82. (Pubitemid 12118742)
116. Loo, T. W.; Clarke, D. M. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem., 1997, 272, 709-712.
117. Van Goor, F.; Straley, K. S.; Cao, D.; González, J.; Hadida, S.; Hazlewood, A.; Joubran, J.; Knapp, T.; Makings, L. R.; Miller, M.; Neuberger, T.; Olson, E.; Panchenko, V.; Rader, J.; Singh, A.; Stack, J. H.; Tung, R.; Grootenhuis, P. D.; Negulescu, P. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006, 290, L1117-1130.
118. Van Laere, A. Trehalose, reserve and/or stress metabolyte? FEMS Microbiol. Rev., 1989, 63, 201-210.
119. Felix, C. F.; Moreira, C. C.; Oliveira, M. A.; Sola-Penna, M.; Meyer-Fernandes, J. R.; Scofano, H. M.; Ferreira-Pereora, A. Protection against thermal denaturation by trehalose on the plasma membrane H+-ATPase from yeast. Synergetic effect between trehalose and phopsholipid environment. Eur. J. Biochem., 1999, 266, 660-664.
120. Arora, A.; Ha, C.; Park, C. B. Inhibition of insulin amyloid formation by small stress molecules. FEBS Lett., 2004, 564, 121-125.
121. Tanaka, M.; Machida, Y.; Niu, S.; Lkeda, T.; Jana, N. R.; Doi, H.; Kurosawa, M.; Nekooki, M.; Nukina, N. Trehalose alleviates polyglutamine- mediated pathology in a mouse model of Huntington disease. Nat. Med., 2004, 10, 148-154.
122. Tanaka, M.; Machida, Y.; Nukina, N. A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregatio-prone proteins with small molecules. J. Mol. Med., 2005, 83, 343-352.
123. Scherzinger, E.; Lurz, R.; Turmaine, M.; Hollenbach, B.; Hasenbank, R.; Bates, G. P.; Davies, S. W.; Lehrach, H.; Wanker, E. E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell., 1997, 90, 549-558.
124. Davies, S. W.; Turmaine, M.; Cozens, B. A.; DiFiglia, M.; Sharp, A. H.; Ross, C. A.; Scherzinger, E.; Wanker, E. E.; Mangiarini, L.; Bates, G. P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell., 1997, 90, 537-548.
125. Michalik, A.; Van Broeckhoven, C. Pathogenesis of polyglutamine disorderes: aggregation revisited. Hum. Mol. Genet., 2003. 12, R173-186.
126. Ross, C. A.; Poirier, M. A.; Wanker, E. E.; Amzel, M. Polyglutamine fibrillogenesis: the pathway unfolds. Proc. Natl. Acad. Sci. USA., 2003, 100, 1-3.
127. Heiser, V.; Scherzinger, E.; Boeddrich, A.; Nordhoff, E.; Lurz, R.; Schugardt, N.; Lehrach, H.; Wanker, E. E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. USA., 2000, 97, 6739-6744.
128. Hughes, R. E.; Olson, J. M. Therapeutic opportunities in polyglutamine disease. Nat. Med., 2001, 7, 419-423.
129. Tanaka, M.; Morishima, I.; Akagi, T.; Hashikawa, T.; Nukina, N. Intra-and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem., 2001, 276, 45470-45475.
130. Tanaka, M.; Machida, Y.; Nishikawa, Y.; Akagi, T.; Hashikawa, T.; Fujisawa, T.; Nukina, N. Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J. Biol. Chem., 2003, 278, 34717-34724.
131. Tanaka, M.; Machida, Y.; Nishikawa, Y.; Akagi, T.; Morishima, I.; Hashikawa, T.; Fujisawa, T.; Nukina, N. The effects of aggregation-inducing motifs on amyloid formation of model proteins related to neurodegenerative diseases. Biochemistry, 2002, 41, 10277-10286.
132. Singer, M.; Lindquist, S. Multiple effects of trehalsoe on protein folding in vitro and in vivo. Mol. Cell, 1998, 1, 639-648.
133. Brown, C. R.; Hong-Brown, L. Q.; Welch, W. J. Strategies for correcting the delta F508 CFTR protein-folding defect. J. Bioenerg. Biomembr., 1997, 29, 491-502.
134. Davies, J. E.; Sarker, S.; Rubinsztein, D. C. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 2006, 15, 23-31.
135. Kita, Y.; Arakawa, T.; Lin, T. Y.; Timasheff, S. N. Contribution of the surface free energy perturbation to protein-solvent interactions. Biochemistry, 1994, 33, 15178-15189.
136. Schneider, C. P.; Trout, B. L. Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J. Phys. Chem., 2009, 113, 2050-2058.
137. Robben, J. H.; Sze, M.; Knoers, N. V.; Deen, P. M. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol. Biol. Cell., 2006, 17, 379-386.